Stock Price Movement and Market Context
On 29 Dec 2025, Samrat Pharmachem Ltd’s share price touched an intraday low of Rs.224.95, representing a 2.41% decline on the day. This move extended the stock’s losing streak to two consecutive sessions, during which it has shed 3.52% in value. The stock’s current price is substantially below its 52-week high of Rs.425, indicating a depreciation of nearly 47% from that peak.
The stock’s performance today notably lagged behind its Pharmaceuticals & Biotechnology sector, underperforming by 2.14%. Additionally, Samrat Pharmachem is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend.
In contrast, the broader market benchmark, the Sensex, opened flat but traded slightly lower by 0.2% at 84,868.50 points, remaining just 1.52% shy of its 52-week high of 86,159.02. The Sensex continues to trade above its 50-day and 200-day moving averages, reflecting a generally bullish market environment that Samrat Pharmachem has not mirrored.
Financial Performance and Valuation Concerns
Samrat Pharmachem’s financial metrics have contributed to its subdued market performance. The company reported flat results in the quarter ending September 2025, with operating cash flow at a low of Rs. -10.09 crores and PBDIT for the quarter registering a loss of Rs. -0.36 crores. The operating profit to net sales ratio also declined to a negative 0.46%, underscoring margin pressures.
Return on equity (ROE) stands at a modest 2.2%, which, when combined with a price-to-book value of 1, suggests that the stock is trading at a premium relative to its fundamental returns. This valuation is considered expensive compared to peers’ historical averages within the Pharmaceuticals & Biotechnology sector.
Over the past year, the company’s profits have contracted sharply by 75.9%, while the stock price has declined by 41.67%. This contrasts with the Sensex’s positive return of 7.79% over the same period, highlighting the stock’s consistent underperformance against the benchmark.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
See This Week's Special Pick →
Long-Term Performance and Market Sentiment
Samrat Pharmachem has demonstrated consistent underperformance over the last three years, failing to match returns generated by the BSE500 index in each annual period. The stock’s cumulative return of -41.67% over the past year further emphasises this trend.
The company’s Mojo Score currently stands at 16.0, with a Mojo Grade of Strong Sell as of 19 Aug 2025, an upgrade from the previous Sell rating. This grading reflects the company’s weak long-term fundamental strength, driven by operating losses and valuation concerns.
Market capitalisation grading remains low at 4, indicating limited market size and liquidity relative to larger peers in the Pharmaceuticals & Biotechnology sector.
Shareholding and Institutional Activity
Foreign Institutional Investors (FIIs) have increased their holdings in Samrat Pharmachem during the current quarter, now holding 3.24% of the company’s shares. This marginal increase in institutional interest contrasts with the stock’s declining price trend, suggesting selective accumulation despite broader market pressures.
Samrat Pharmachem Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Metrics
To summarise, Samrat Pharmachem Ltd’s stock has reached a 52-week low of Rs.224.95, reflecting a sustained decline amid weak financial results and valuation pressures. The stock’s underperformance relative to the Sensex and its sector peers is marked, with a one-year return of -41.67% against the benchmark’s positive 7.79%.
Operating cash flows remain negative at Rs. -10.09 crores, and quarterly PBDIT losses persist at Rs. -0.36 crores. The company’s operating profit margin has dipped below zero, and ROE remains low at 2.2%. Despite these challenges, FIIs have marginally increased their stake, holding 3.24% of the company.
Samrat Pharmachem’s current trading below all major moving averages further highlights the prevailing downward momentum in the stock price.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
